Bill
Bill > A3648
NJ A3648
NJ A3648Establishes three-year Medicaid demonstration project to pay for certain drugs according to value-based system.
summary
Introduced
02/12/2024
02/12/2024
In Committee
02/12/2024
02/12/2024
Crossed Over
Passed
Dead
01/12/2026
01/12/2026
Introduced Session
2024-2025 Regular Session
Bill Summary
This bill establishes a three-year Medicaid demonstration project to pay for certain drugs according to a value-based payment system. Under the bill, the Department of Human Services will establish a three-year demonstration project to employ value-based payment systems for a limited number of prescription drugs covered under the program. The department will enter into purchasing or rebate agreements with the manufacturers of at least three different prescription drugs, which will provide that the total reimbursement paid by the State for such drugs will be based in some part on observed outcomes of the drug's use in patients. The drugs selected for the demonstration project will have specific therapeutic purposes with outcomes that are readily measurable with existing data systems, and will be among the highest-cost drugs in the New Jersey Medicaid program in aggregate spending. The department and the manufacturer of each drug selected for the project must agree to the best terms to accommodate the chosen value-based purchasing or rebate agreement based on other value-based agreements with manufacturers that take into consideration observed outcomes of the drug's use in patients. The department will require that Medicaid managed care organizations participate in the demonstration project, and will specify the obligations of the managed care organizations under the demonstration program in the contract between the department and the managed care organizations. After the expiration of the three-year demonstration project, the Commissioner of Human Services will report to the Governor and Legislature on the results of the demonstration project, along with the commissioner's recommendations on the advisability of re-establishing, expanding, or otherwise modifying the project. The report shall include specific performance test results, which have been aggregated and de-identified as necessary to protect patients' identities and health information protected by State and federal law.
AI Summary
This bill establishes a three-year Medicaid demonstration project to pay for certain high-cost prescription drugs according to a value-based payment system. The Department of Human Services will enter into purchasing or rebate agreements with the manufacturers of at least three different drugs, where the total reimbursement paid by the state will be based in part on the observed outcomes of the drug's use in patients. The selected drugs will have specific therapeutic purposes with readily measurable outcomes, and will be among the highest-cost drugs in the New Jersey Medicaid program. The department and the manufacturers must agree on the best terms to accommodate the value-based agreements, and Medicaid managed care organizations will be required to participate. After the three-year project, the Commissioner of Human Services will report on the results and provide recommendations on whether to re-establish, expand, or modify the project.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Introduced, Referred to Assembly Aging and Human Services Committee (on 02/12/2024)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2024/A3648 |
| BillText | https://pub.njleg.gov/Bills/2024/A4000/3648_I1.HTM |
Loading...